00867.HK
China Medical System Holdings Limited
HKSE · Healthcare · Drug Manufacturers - Specialty & Generic · HK
HKD 11.04
−0.36%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 16.5B | 8.2B | 7.5B | 8.0B | 9.2B |
| Cost of Revenue | 4.7B | 2.3B | 2.0B | 1.9B | 2.1B |
| Gross Profit | 11.8B | 5.9B | 5.4B | 6.1B | 7.0B |
| Operating Expenses | |||||
| R&D Expense | 1.2B | 585.0M | 330.0M | 195.1M | 125.4M |
| SG&A Expense | 7.2B | 3.7B | 3.4B | 3.2B | 3.4B |
| General & Admin Expense | 1.3B | 865.8M | 780.1M | 656.6M | 636.6M |
| Selling & Marketing Expense | 4.1B | 2.8B | 2.7B | 2.5B | 2.7B |
| Other Expenses | (82.0M) | — | (82.0M) | — | (93.1M) |
| Total Operating Expenses | 8.3B | 4.3B | 3.7B | 3.4B | 3.4B |
| Cost and Expenses | 13.0B | 6.6B | 5.7B | 5.3B | 5.5B |
| Operating Income (EBIT) | 3.5B | 1.6B | 1.7B | 2.7B | 3.6B |
| Non-Operating | |||||
| Interest Income | 187.4M | 82.3M | 126.3M | 146.5M | 105.5M |
| Interest Expense | 55.5M | 20.3M | 38.6M | 46.3M | 49.1M |
| Net Interest Income | 131.8M | 62.1M | 87.7M | 100.2M | 56.4M |
| Other Non-Op Income/Expense | 689.8M | 524.6M | 277.8M | 160.9M | 210.4M |
| Non-Operating Income (excl Interest) | (316.4M) | — | (316.4M) | (88.3M) | — |
| EBT (Pre-Tax Income) | 4.2B | 2.1B | 2.0B | 2.9B | 3.8B |
| Income Tax Expense | 1.0B | 659.8M | 397.2M | 489.3M | 486.7M |
| Bottom Line | |||||
| Net Income | 3.2B | 1.5B | 1.6B | 2.4B | 3.3B |
| Earnings from Cont. Ops | 3.1B | 1.4B | 1.6B | 2.4B | 3.3B |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | 3.2B | 1.5B | 1.6B | 2.4B | 3.3B |
| Per Share | |||||
| Basic EPS | HK$1.30 | HK$0.62 | HK$0.67 | HK$0.98 | HK$1.33 |
| Diluted EPS | HK$1.30 | HK$0.62 | HK$0.67 | HK$0.98 | HK$1.33 |
| Revenue Per Share | HK$6.82 | HK$3.39 | HK$3.08 | HK$3.27 | HK$3.73 |
| Shares | |||||
| Basic Shares Outstanding | 2.4B | 2.4B | 2.4B | 2.5B | 2.5B |
| Diluted Shares Outstanding | 2.4B | 2.4B | 2.4B | 2.5B | 2.5B |
| Profitability Metrics | |||||
| EBITDA | 4.3B | 1.8B | 2.3B | 2.9B | 3.8B |
| D&A | 522.1M | 246.3M | 259.2M | 209.3M | 209.1M |
| EBIT | 3.8B | 1.6B | 2.0B | 2.7B | 3.6B |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026